FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> GlaxoSmithKline | AstraZeneca | Shire

SPOTLIGHT: Investors expected to boost GSK, AZ

Tools


Credit Suisse lifted its share-price targets for GlaxoSmithKline, AstraZeneca, and Shire, saying it expects the pharma sector to be something of a port in a storm for investors worried about the economy. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:
Be the first to comment
More stories about GlaxoSmithKline   AstraZeneca   Shire  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.